Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Medications for Diabetes Management Have Additional Heart Benefits

By Ana Gajic, St. Michael's Hospital | August 29, 2018

A drug used to manage diabetes may reduce heart disease and death in people with diabetes regardless of their cholesterol levels and whether they are on a statin therapy, suggests a new analysis of the LEADER trial.

The analysis suggests people with Type 2 diabetes and high cardiovascular risk have a lowered risk of death from heart attack, nonfatal heart attack and nonfatal stroke when receiving liraglutide treatment, regardless of their low-density lipoprotein cholesterol (LDL-C) levels and whether they are concurrently taking statins. Liraglutide is a medication that works through various mechanisms to help reduce blood sugar.

Dr. Subodh Verma, cardiac surgeon-scientist and director of the CardioLink platform at the Keenan Research Centre for Biomedical Science (KRCBS) of St. Michael’s Hospital in Canada, presented these findings at the European Society of Cardiology Annual Congress in Munich, Germany. They were published simultaneously in Circulation. Dr. Lawrence Leiter, director of the Lipid Clinic at St. Michael’s, and Dr. David Mazer, associate scientist at the KRCBS co-led the study. St. Michael’s was one of more than 400 international sites to participate in the LEADER trial, an FDA-mandated randomized control trial involving more than 9,300 patients with Type 2 diabetes to evaluate liraglutide and its effects on heart disease.

“One of the many ways in which we reduce heart disease is by treating people with statins to lower their cholesterol,” Verma said. “This work brings us closer to understanding whether there is further benefit of newer agents that treat diabetes and whether those benefits persist in people who are taking statins.”

LDL-C levels are an important marker of developing heart disease. Higher levels of LDL-C are associated with increased risks of cardiovascular disease. Statins are lipid-lowering medications that lower the risk of heart disease.

Verma said these results are exciting as they show there are more options to lowering heart disease risk in people with diabetes than the use of statins alone.

“This analysis suggests that we have another tool in our armamentarium to further reduce risk for people who have Type 2 diabetes,” he said.

This study was funded by Novo Nordisk, the pharmaceutical company that developed liraglutide.

SOURCE: St. Michael’s Hospital


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE